ATE552012T1 - Hemmung des abnormalen wachstums von synovialzellen durch il-6-antagonisten als wirkstoff - Google Patents

Hemmung des abnormalen wachstums von synovialzellen durch il-6-antagonisten als wirkstoff

Info

Publication number
ATE552012T1
ATE552012T1 AT95921130T AT95921130T ATE552012T1 AT E552012 T1 ATE552012 T1 AT E552012T1 AT 95921130 T AT95921130 T AT 95921130T AT 95921130 T AT95921130 T AT 95921130T AT E552012 T1 ATE552012 T1 AT E552012T1
Authority
AT
Austria
Prior art keywords
antagonists
inhibition
active substance
abnormal growth
synovial cells
Prior art date
Application number
AT95921130T
Other languages
English (en)
Inventor
Tadamitsu Kishimoto
Masahiko Mihara
Yoichiro Moriya
Yoshiyuki Ohsugi
Original Assignee
Chugai Pharmaceutical Co Ltd
Tadamitsu Kishimoto
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=17112746&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE552012(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Chugai Pharmaceutical Co Ltd, Tadamitsu Kishimoto filed Critical Chugai Pharmaceutical Co Ltd
Application granted granted Critical
Publication of ATE552012T1 publication Critical patent/ATE552012T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/248—IL-6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
AT95921130T 1994-10-07 1995-06-07 Hemmung des abnormalen wachstums von synovialzellen durch il-6-antagonisten als wirkstoff ATE552012T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP24403594 1994-10-07
PCT/JP1995/001144 WO1996011020A1 (en) 1994-10-07 1995-06-07 Rheumatoid arthritis remedy containing il-6 antagonist as active ingredient

Publications (1)

Publication Number Publication Date
ATE552012T1 true ATE552012T1 (de) 2012-04-15

Family

ID=17112746

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95921130T ATE552012T1 (de) 1994-10-07 1995-06-07 Hemmung des abnormalen wachstums von synovialzellen durch il-6-antagonisten als wirkstoff

Country Status (18)

Country Link
EP (3) EP2107070A1 (de)
JP (1) JP3067987B2 (de)
KR (1) KR100306517B1 (de)
CN (2) CN101601861A (de)
AT (1) ATE552012T1 (de)
AU (1) AU700819B2 (de)
CA (1) CA2201781C (de)
CZ (1) CZ296919B6 (de)
DK (1) DK0783893T3 (de)
ES (1) ES2384222T3 (de)
FI (1) FI120721B (de)
HU (1) HU223602B1 (de)
LU (1) LU92048I2 (de)
NO (4) NO321089B1 (de)
PL (1) PL186506B1 (de)
PT (1) PT783893E (de)
RU (1) RU2147443C1 (de)
WO (1) WO1996011020A1 (de)

Families Citing this family (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100838862B1 (ko) * 1997-03-21 2008-06-16 츄가이 세이야꾸 가부시키가이샤 아이엘-6 안타고니스트를 유효성분으로 함유하는 감작 티 세포 관여 질환의 예방 또는 치료제
DE69839517D1 (de) * 1997-08-15 2008-07-03 Chugai Pharmaceutical Co Ltd Präventiva oder arzneien enthaltend neutralisierende anti-il6-rezeptor antikörper zur reduktion urinären proteins bei systemischen lupus erythematosus
CA2324115C (en) 1998-03-17 2008-12-23 Chugai Seiyaku Kabushiki Kaisha A preventive or therapeutic agent for inflammatory bowel disease comprising il-6 antagonist as an active ingredient
CA2294045C (en) 1998-04-17 2010-06-08 Suntory Limited Gene encoding a protein having aurone synthesis activity
AU1095202A (en) 2000-10-25 2002-05-06 Chugai Pharmaceutical Co Ltd Preventives or remedies for psoriasis containing as the active ingredient il-6 antagonist
US20050074434A1 (en) * 2001-02-23 2005-04-07 Tomoaki Hoshino Remedies for metabolic bone diseases
UA80091C2 (en) * 2001-04-02 2007-08-27 Chugai Pharmaceutical Co Ltd Remedies for infant chronic arthritis-relating diseases and still's disease which contain an interleukin-6 (il-6) antagonist
DE60229509D1 (de) * 2001-04-05 2008-12-04 Astellas Pharma Inc Anti-osteopontin-antikörper und dessen verwendung
MXPA04007924A (es) 2002-02-14 2005-05-17 Chugai Pharmaceutical Co Ltd Formulaciones en solucion que contienen anticuerpo.
GB2401040A (en) 2003-04-28 2004-11-03 Chugai Pharmaceutical Co Ltd Method for treating interleukin-6 related diseases
JP2007104901A (ja) * 2004-01-16 2007-04-26 Astellas Pharma Inc 関節リウマチ治療薬のスクリーニング法
JP2008505054A (ja) * 2004-02-11 2008-02-21 ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー Ｉｌ−６アンタゴニストで骨関節炎を治療する方法
AR048335A1 (es) 2004-03-24 2006-04-19 Chugai Pharmaceutical Co Ltd Agentes terapeuticos para trastornos del oido interno que contienen un antagonista de il- 6 como un ingrediente activo
RU2293559C2 (ru) * 2005-03-09 2007-02-20 Лидия Николаевна Долгова Способ подготовки к любрикантной терапии
RU2293560C2 (ru) * 2005-03-09 2007-02-20 Лидия Николаевна Долгова Способ лечения хронических гонартритов у больных остеоартрозом
DK3050963T3 (da) 2005-03-31 2019-12-09 Chugai Pharmaceutical Co Ltd Fremgangsmåde til fremstilling af polypeptid ved regulering af arrangement
PA8672101A1 (es) * 2005-04-29 2006-12-07 Centocor Inc Anticuerpos anti-il-6, composiciones, métodos y usos
RU2441067C2 (ru) * 2005-09-28 2012-01-27 Цитос Биотехнологи Аг Конъюгаты интерлейкина-1 и их применение
CA2625773C (en) 2005-10-14 2015-05-12 Fukuoka University Inhibition of interleukin-6 (il-6) receptor promotes pancreatic islet transplantation
KR101239051B1 (ko) 2005-10-21 2013-03-04 추가이 세이야쿠 가부시키가이샤 심장질환 치료제
AR057582A1 (es) 2005-11-15 2007-12-05 Nat Hospital Organization Agentes para suprimir la induccion de linfocitos t citotoxicos
US8771686B2 (en) 2006-01-27 2014-07-08 Chugai Seiyaku Kabushiki Kaisha Methods for treating a disease involving choroidal neovascularization by administering an IL-6 receptor antibody
DK2009101T3 (en) 2006-03-31 2018-01-15 Chugai Pharmaceutical Co Ltd Antibody modification method for purification of a bispecific antibody
EP2006381B1 (de) 2006-03-31 2016-02-03 Chugai Seiyaku Kabushiki Kaisha Verfahren zur kontrolle der blut-pharmakokinetik von antikörpern
WO2007116962A1 (ja) 2006-04-07 2007-10-18 Osaka University 筋再生促進剤
NZ573557A (en) 2006-06-02 2010-08-27 Regeneron Pharma High affinity antibodies to human il-6 receptor
US8080248B2 (en) 2006-06-02 2011-12-20 Regeneron Pharmaceuticals, Inc. Method of treating rheumatoid arthritis with an IL-6R antibody
AU2007282023B2 (en) 2006-08-03 2012-09-13 Vaccinex, Inc. Anti-IL-6 monoclonal antibodies and uses thereof
JP2010095445A (ja) * 2006-12-27 2010-04-30 Tokyo Medical & Dental Univ Ｉｌ−６アンタゴニストを有効成分とする炎症性筋疾患治療剤
ES2564392T3 (es) 2007-01-23 2016-03-22 Shinshu University Inhibidores de IL-6 para el tratamiento de rechazo crónico
CL2008002886A1 (es) 2007-09-26 2009-12-04 Chugai Pharmaceutical Co Ltd Region constante de un anticuerpo humano; anticuerpo anti-receptor de interleucina-6 (il-6) y composicion farmaceutica que la comprende.
RU2505603C2 (ru) 2007-09-26 2014-01-27 Чугаи Сейяку Кабусики Кайся Антитело против рецептора il-6
CA2700701C (en) 2007-09-26 2020-12-29 Chugai Seiyaku Kabushiki Kaisha Method of modifying isoelectric point of antibody via amino acid substitution in cdr
WO2009072604A1 (ja) 2007-12-05 2009-06-11 Chugai Seiyaku Kabushiki Kaisha 抗nr10抗体、およびその利用
NZ717429A (en) 2008-04-11 2018-07-27 Chugai Pharmaceutical Co Ltd Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly
US8034344B2 (en) 2008-05-13 2011-10-11 Novimmune S.A. Anti-IL-6/IL-6R antibodies and methods of use thereof
KR101665729B1 (ko) 2008-06-05 2016-10-12 국립연구개발법인 고쿠리츠간켄큐센터 신경침윤 억제제
US8188235B2 (en) 2008-06-18 2012-05-29 Pfizer Inc. Antibodies to IL-6 and their uses
TWI440469B (zh) 2008-09-26 2014-06-11 Chugai Pharmaceutical Co Ltd Improved antibody molecules
WO2010107110A1 (ja) 2009-03-19 2010-09-23 中外製薬株式会社 抗体定常領域改変体
EP2826789A1 (de) 2009-03-19 2015-01-21 Chugai Seiyaku Kabushiki Kaisha Variante einer konstanten Region eines Antikörpers
CN102459344A (zh) 2009-05-15 2012-05-16 中外制药株式会社 抗axl抗体
EP2432480B1 (de) * 2009-05-18 2021-05-05 The University of Hong Kong Zusammensetzungen und verfahren zur behandlung entzündlicher arthritis
EP2481752B1 (de) 2009-09-24 2016-11-09 Chugai Seiyaku Kabushiki Kaisha Modifizierte konstante antikörperregionen
JO3417B1 (ar) 2010-01-08 2019-10-20 Regeneron Pharma الصيغ المستقرة التي تحتوي على الأجسام المضادة لمضاد مستقبل( interleukin-6 (il-6r
AR080428A1 (es) 2010-01-20 2012-04-11 Chugai Pharmaceutical Co Ltd Formulaciones liquidas estabilizadas contentivas de anticuerpos
WO2011108714A1 (ja) 2010-03-04 2011-09-09 中外製薬株式会社 抗体定常領域改変体
US20130149302A1 (en) 2010-05-28 2013-06-13 Chugai Seiyaku Kabushiki Kaisha Therapeutic agents for pancreatic cancer
PL2578231T3 (pl) 2010-05-28 2023-01-16 Chugai Seiyaku Kabushiki Kaisha Środek wzmacniający przeciwnowotworową odpowiedź limfocytów t
CN104998254A (zh) 2010-11-08 2015-10-28 基因技术公司 皮下施用的抗-il-6受体抗体
MX355060B (es) 2010-11-17 2018-04-03 Chugai Pharmaceutical Co Ltd Molecula multiespecifica de union a antigeno que tiene funcion alternativa a la funcion del factor viii de coagulacion sanguinea.
CN108715614A (zh) 2010-11-30 2018-10-30 中外制药株式会社 与多分子的抗原重复结合的抗原结合分子
JP4987117B2 (ja) 2010-12-27 2012-07-25 中外製薬株式会社 Ｉｌ−６アンタゴニストを有効成分として含有する血中ｍｍｐ−３濃度低下剤
CN112812184A (zh) 2011-02-25 2021-05-18 中外制药株式会社 FcγRIIb特异性Fc抗体
US20150050269A1 (en) 2011-09-30 2015-02-19 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule promoting disappearance of antigens having plurality of biological activities
TW201817745A (zh) 2011-09-30 2018-05-16 日商中外製藥股份有限公司 具有促進抗原清除之ＦｃＲｎ結合域的治療性抗原結合分子
TWI589299B (zh) 2011-10-11 2017-07-01 再生元醫藥公司 用於治療類風濕性關節炎之組成物及其使用方法
EP2791169B1 (de) 2011-12-16 2017-07-19 Synthon Biopharmaceuticals B.V. Verbindungen und verfahren zur behandlung von entzündungserkrankungen
WO2013176471A1 (ko) 2012-05-21 2013-11-28 한국생명공학연구원 곰보배추의 추출물 또는 이의 분획물을 유효성분으로 포함하는, stat3 매개 질환의 예방 또는 치료용 약학적 조성물
EP3009518B1 (de) 2013-06-11 2020-08-12 National Center of Neurology and Psychiatry Verfahren zur vorhersage einer posttherapeutischen prognose von patienten mit schubförmig remittierender multipler sklerose (rrms) und verfahren zur bestimmung der anwendbarkeit der neuartigen therapie
MX382731B (es) 2013-09-27 2025-03-13 Chugai Pharmaceutical Co Ltd Metodo para producir heteromultimeros de polipeptidos.
US9017678B1 (en) 2014-07-15 2015-04-28 Kymab Limited Method of treating rheumatoid arthritis using antibody to IL6R
MA40764A (fr) 2014-09-26 2017-08-01 Chugai Pharmaceutical Co Ltd Agent thérapeutique induisant une cytotoxicité
TWI617580B (zh) 2014-12-19 2018-03-11 中外製藥股份有限公司 抗ｃ５抗體及使用方法
KR102650420B1 (ko) 2014-12-19 2024-03-21 추가이 세이야쿠 가부시키가이샤 항-마이오스타틴 항체, 변이체 Fc 영역을 함유하는 폴리펩타이드, 및 사용 방법
KR102605798B1 (ko) 2015-02-05 2023-11-23 추가이 세이야쿠 가부시키가이샤 이온 농도 의존적 항원 결합 도메인을 포함하는 항체, Fc 영역 개변체, IL-8에 결합하는 항체, 및 그들의 사용
EP4269440A3 (de) 2015-02-27 2024-02-28 Chugai Seiyaku Kabushiki Kaisha Zusammensetzung zur behandlung von il-6-assoziierten erkrankungen
WO2016159213A1 (ja) 2015-04-01 2016-10-06 中外製薬株式会社 ポリペプチド異種多量体の製造方法
EP3299810B1 (de) 2015-05-19 2021-07-07 National Center of Neurology and Psychiatry Verfahren zur bestimmung der anwendung einer neuartigen therapie bei patienten mit multipler sklerose (ms)
US11174317B2 (en) 2015-06-04 2021-11-16 National Center Of Neurology And Psychiatry Therapeutic agent for mental illness comprising IL-6 inhibitor as active ingredient
KR20180073680A (ko) 2015-11-03 2018-07-02 사노피 바이오테크놀로지, 소시에떼 빠르 악씨옹 셍쁠리피에 포도막염 및 황반 부종의 치료를 위한 il6r 항체를 포함하는 조성물 및 이를 이용하는 방법
JP7141336B2 (ja) 2015-12-25 2022-09-22 中外製薬株式会社 抗ミオスタチン抗体および使用方法
MX2018007781A (es) 2015-12-28 2018-09-05 Chugai Pharmaceutical Co Ltd Metodo para promover la eficiencia de purificacion del polipeptido que contiene la region de fragmento cristalizable (fc).
WO2017159287A1 (ja) 2016-03-14 2017-09-21 中外製薬株式会社 癌の治療に用いるための細胞傷害誘導治療剤
EP3449940B1 (de) 2016-04-28 2025-11-19 Chugai Seiyaku Kabushiki Kaisha Antikörperhaltiges präparat
TW202300168A (zh) 2016-08-05 2023-01-01 日商中外製藥股份有限公司 Il-8相關疾病之治療用或預防用組成物
CN108339118A (zh) * 2017-01-23 2018-07-31 瑞阳(苏州)生物科技有限公司 治疗或预防阻塞性睡眠呼吸暂停的药物组合物
EP3620531A4 (de) 2017-05-02 2021-03-17 National Center of Neurology and Psychiatry Verfahren zur vorhersage und beurteilung der therapeutischen wirkung bei erkrankungen im zusammenhang mit il-6 und neutrophilen
JP2021500856A (ja) 2017-09-13 2021-01-14 江蘇恒瑞医薬股▲ふん▼有限公司 Ｉｌ−６ｒ抗体およびその抗原結合フラグメントならびに医薬としての使用
WO2019078344A1 (ja) 2017-10-20 2019-04-25 学校法人兵庫医科大学 抗ｉｌ－６受容体抗体を含有する術後の癒着を抑制するための医薬組成物
BR112020008393A2 (pt) 2017-11-01 2020-11-03 Chugai Seiyaku Kabushiki Kaisha variante e isoforma de anticorpos com atividade biológica reduzida
JP7504871B2 (ja) 2018-08-29 2024-06-24 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 関節リウマチを有する対象を治療するための方法および組成物
CN109517064B (zh) * 2018-10-10 2020-05-08 北京汇智和源生物技术有限公司 白介素-6的人源化单克隆抗体、其编码基因及应用
AU2020216978B2 (en) 2019-01-31 2025-09-25 Regeneron Pharmaceuticals, Inc. Anti-il-6 receptor antibody for treating juvenile idiopathic arthritis
WO2020178193A1 (en) 2019-03-01 2020-09-10 INSERM (Institut National de la Santé et de la Recherche Médicale) Method of treatment of sarcoidosis
MA55760A (fr) 2019-04-24 2022-03-02 Regeneron Pharma Procédés de diagnostic et de traitement de la polyarthrite rhumatoïde
BR112021024445A2 (pt) 2019-06-04 2022-02-15 Regeneron Pharma Composições e métodos para tratamento de dor em indivíduos com artrite reumatoide

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1341152C (en) 1988-01-22 2000-12-12 Tadamitsu Kishimoto Receptor protein for human b cell stimulatory factor-2
EP0399429A1 (de) * 1989-05-22 1990-11-28 Toray Industries, Inc. Monoklonaler Antikörper gegen menschliches Interleukin-6
CA2021594C (en) * 1989-07-20 2002-01-08 Tadamitsu Kishimoto Antibody to human interleukin-6 receptor
JP2898064B2 (ja) 1989-08-03 1999-05-31 忠三 岸本 ヒトｇｐ１３０蛋白質
DE3939706C1 (de) * 1989-12-01 1991-03-21 Centre Regional De Transfusion Sanguine, Besancon, Fr
DE69006221T2 (de) * 1989-12-04 1994-05-05 Fletcher Starnes H Verfahren zur behandlung von septischem schock.
JP2898040B2 (ja) 1990-01-26 1999-05-31 忠三 岸本 ｇｐ１３０蛋白質に対する抗体
US5210075A (en) * 1990-02-16 1993-05-11 Tanabe Seiyaku Co., Ltd. Interleukin 6 antagonist peptides
JPH0489433A (ja) 1990-07-27 1992-03-23 Hitachi Chem Co Ltd 免疫調節剤
JP2947924B2 (ja) * 1990-11-21 1999-09-13 信和化工株式会社 光学異性体用分離剤
JPH04187645A (ja) * 1990-11-22 1992-07-06 Chuzo Kishimoto インターロイキン―６作用抑制剤
DE122009000019I1 (de) 1991-04-25 2009-07-16 Chugai Seiyaku K K 5 1 Rekombinierte humane antikörper gegen den humanen interleukin-6 rezeptor
JPH05300338A (ja) 1992-04-17 1993-11-12 Ricoh Co Ltd 複合機
JPH05304986A (ja) * 1992-04-28 1993-11-19 Tosoh Corp ｇｐ１３０蛋白質に対するモノクロ−ナル抗体
FR2694767B1 (fr) * 1992-08-13 1994-10-21 Innotherapie Lab Sa Anticorps monoclonaux anti-IL6R, et leurs applications.
JPH06134617A (ja) 1992-10-23 1994-05-17 Amada Co Ltd 鋸盤の鋸刃テンション自動調整装置
JP3525221B2 (ja) * 1993-02-17 2004-05-10 味の素株式会社 免疫抑制剤

Also Published As

Publication number Publication date
LU92048I2 (fr) 2012-09-20
AU700819B2 (en) 1999-01-14
RU2147443C1 (ru) 2000-04-20
JP3067987B2 (ja) 2000-07-24
EP0783893A1 (de) 1997-07-16
HUT77036A (hu) 1998-03-02
PT783893E (pt) 2012-05-24
HU223602B1 (hu) 2004-10-28
EP2077120A3 (de) 2009-07-15
EP0783893A4 (de) 1998-04-22
CA2201781C (en) 2010-01-12
CN101601861A (zh) 2009-12-16
NO2009009I2 (no) 2013-03-18
PL186506B1 (pl) 2004-01-30
AU2630395A (en) 1996-05-02
FI971404L (fi) 1997-06-03
EP2107070A1 (de) 2009-10-07
HK1127497A1 (en) 2009-09-25
NO20055446L (no) 1997-06-04
CN101361972A (zh) 2009-02-11
NO2018017I1 (no) 2018-05-23
EP0783893B1 (de) 2012-04-04
NO971546L (no) 1997-06-04
KR100306517B1 (ko) 2001-11-30
NO321089B1 (no) 2006-03-13
DK0783893T3 (da) 2012-05-29
CZ103497A3 (en) 1997-08-13
EP2077120A2 (de) 2009-07-08
NO2009009I1 (no) 2009-05-11
FI120721B (fi) 2010-02-15
JPH08208514A (ja) 1996-08-13
CA2201781A1 (en) 1996-04-18
FI971404A0 (fi) 1997-04-04
CZ296919B6 (cs) 2006-07-12
WO1996011020A1 (en) 1996-04-18
PL319574A1 (en) 1997-08-18
ES2384222T3 (es) 2012-07-02
NO971546D0 (no) 1997-04-04
CN101361972B (zh) 2011-05-25

Similar Documents

Publication Publication Date Title
ATE552012T1 (de) Hemmung des abnormalen wachstums von synovialzellen durch il-6-antagonisten als wirkstoff
RU97108276A (ru) Лечебные средства против хронического ревматоидного артрита, содержащие антагонист il-6 в качестве эффективного компонента
EA200000868A1 (ru) Ингибиторы фосфолипаз
TR199801255T2 (xx) Vitronektin resept�r antagonistleri.
BR9907256A (pt) Inibidores beta-cetoamida de proteassoma 20s
ATE232204T1 (de) Neue sulfonamide
TR199801253T2 (xx) Vitronektin resept�r� antagonistleri.
NO924326L (no) Antitrombosemidler
NO932620L (no) Amindiol-proteaseinhibitorer
ATE387215T1 (de) Mittel zur prävention oder behandlung von psoriasis mit einem il-6-antagonist als wirkstoff
ATE247644T1 (de) Imidazo-annellierte iso- und heterocyclen, antagonisten als angiotensin ii
MX9602818A (es) Un metodo de tratamiento de infeccion parasitaria usando antagonistas ige.
EA200000768A1 (ru) ЗАМЕЩЕННЫЕ ОКСОАЗАГЕТЕРОЦИКЛИЧЕСКИЕ ИНГИБИТОРЫ ФАКТОРА Ха
DE3485895D1 (de) Verwendung von durch emulgatoren stabilisierte kohlenwasserstoffschlaemme als brennstoffe.
TR200102969T2 (tr) Siklik protein tirozin kinaz önleyicileri.
BR9910359A (pt) Proteìna hìbrida para inibição de desgranulação de mastócitos e seu uso
KR960013371A (ko) 약학적 혼합물
EA200000891A1 (ru) Кристаллическая форма 4-[5-метил-3-фенилизоксазол-4-ил] бензолсульфонамида
AU8330898A (en) Substituted heterocycles and their use in medicaments
DE69942063D1 (de) Antagonisten von 'hedgehog' und 'patched' zur inhibierung des wachstums und der differenzierung von zellen und geweben, als auch deren verwendungen
EA200100607A1 (ru) 3,4,5-тризамещенные арилнитроны и содержащие их фармацевтические композиции
ES2152328T3 (es) Antagonistas del receptor del fibrinogeno.
DK0636247T3 (da) Fremgangsmåde og sammensætning til reduktion af virkningerne af endogen alkalisk phosphatase
DK0732926T3 (da) Farmaceutisk formulering til profylakse eller forbehandling af forgiftninger fremkaldt af organophosphor-cholinesterase-inhibitorer
ATE53492T1 (de) Formulierung von entzuendungshemmenden arzneimitteln.